Skip to main content

Advertisement

Table 3 Definitions of “responders” and “non-responders”, “controlled” and “uncontrolled” symptoms for allergic rhinitis and urticaria

From: Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia

  Allergic rhinitis Urticaria
Responder Improvement of overall symptoms by VAS. VAS decreases by > 50% compared with 4‒6 weeks before treatment OR > 50% improvement in symptoms after 1 week of treatment Absence of, or reduction in number and/or frequency of, urticaria lesions/angioedema OR Complete response: UAS7 score decreases by > 90% from the baseline score Significant improvement: UAS7 score decreases by > 30%, but < 90% from the baseline score
Nonresponder VAS changes < 50% compared with 4‒6 weeks before treatment OR < 20% improvement in symptoms after 1 week of treatment Same (or increase in) number and/or frequency of urticaria lesions/angioedema after treatment of adequate dosage for at least 2 weeks OR UAS7 score decreases by < 30% from the baseline score
Controlled symptoms VAS score < 5/10 at the time of asking the patient OR 80% improvement in symptoms and QoL Improvement or elimination of itch and/or visible lesions and/or QoL (as perceived by patient) OR UAS7 score decreases by > 90% from the baseline score
Uncontrolled symptoms VAS score ≥ 5/10 at the time of asking the patient OR < 50% improvement in symptoms and QoL No change (or worsening) of itch and/or visible lesions and/or quality of life (as perceived by the patient) OR UAS7 score decreases by < 30% from the baseline score or flares up
  1. QoL quality of life, UAS7 weekly urticaria activity score, VAS visual analog scale